27.07.2016 | Icagen Inc.: Entering agreement with Nanion
DURHAM, N.C., LIVINGSTON, N.J. and MUNICH, GERMANY, July 27, 2016 -- Icagen Acquires Nanion's SyncroPatch384 High-Throughput Electrophysiology Platform -- Entering agreement with Nanion to develop and commercialize innovative ion channel drug discovery solutions - assays for two gene families established
Icagen, Inc. and Nanion announced today that Icagen has purchased a SyncroPatch384 high-throughput electrophysiology instrument and entered into an agreement to work together to develop ion channel assays for this platform. The instrument was delivered to Icagen in May 2016 and the company has established assays for two different gene families on the platform to date. Assay panels across specific gene families as well as development of diversity panels such as those used in safety screening across the industry will continually be added.
Read full press release here.
See Icagens validation data on different Sodium channels on the SyncroPatch 384PE here.
Find out more about Icagen here.